The forecasted number of confirmed Rifampicina Resistant/Multi-Drug Resistant Tuberculosis (RR-/MDR-TB) cases in Brazil demonstrates a gradual increase from 1.4 thousand cases in 2024 to 1.55 thousand cases by 2028. The year-on-year variations are 2.86% from 2024 to 2025, 2.78% from 2025 to 2026, and 2.70% from 2026 to 2027, showing a consistent upward trend. From 2023 to 2028, the compound annual growth rate (CAGR) stands at approximately 2.81%, indicating a steady increase in RR-/MDR-TB cases over this five-year period.
Future trends to watch include advancements in tuberculosis diagnostics and treatments, increased health funding, and public health interventions which may impact the incidence rates. Additionally, monitoring the socioeconomic factors that contribute to TB spread could inform targeted strategies to curb the disease's growth in Brazil.
